WallStSmart

InnovAge Holding Corp (INNV)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 7085% more annual revenue ($65.77B vs $915.37M). MRK leads profitability with a 13.6% profit margin vs 0.7%. MRK trades at a lower P/E of 31.5x. MRK earns a higher WallStSmart Score of 53/100 (C-).

INNV

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 4.5Value: 5.7Quality: 6.0
Piotroski: 5/9Altman Z: 1.74

MRK

Buy

53

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 2.7Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INNVUndervalued (+45.5%)

Margin of Safety

+45.5%

Fair Value

$15.02

Current Price

$7.96

$7.06 discount

UndervaluedFair: $15.02Overvalued
MRKSignificantly Overvalued (-15.7%)

Margin of Safety

-15.7%

Fair Value

$97.76

Current Price

$113.56

$15.80 premium

UndervaluedFair: $97.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INNV0 strengths · Avg: 0/10

No standout strengths identified

MRK4 strengths · Avg: 9.5/10
Market CapQuality
$277.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

INNV4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.744/10

Distress zone — elevated risk

Market CapQuality
$1.08B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.2%3/10

ROE of 1.2% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.432/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : INNV

Revenue growth of 14.7% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.

Bear Case : INNV

The primary concerns for INNV are Altman Z-Score, Market Cap, Return on Equity. A P/E of 159.2x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

INNV carries more volatility with a beta of 0.49 — expect wider price swings.

INNV is growing revenue faster at 14.7% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (53/100 vs 31/100). INNV offers better value entry with a 45.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InnovAge Holding Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

InnovAge Holding Corp. The company is headquartered in Denver, Colorado.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?